Notably, conventional CAR-T cells preferentially attacked tumor cells with high and medium EGFR, whereas EGFR-BBζ + CD2 CAR-T cells exhibited a markedly reduced bias (Fig. S10C). Here, CD2 is linked to neoplasm.